Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

828.00 +1.42 (+0.17%)
Streaming Delayed Price Updated: 11:23 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?
A disappointing result for its oral obesity candidate hammered the stock price. 
Via The Motley Fool
Here's Why Viking Therapeutics Bounced Back Today
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing. 
Via The Motley Fool
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny
The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ:... 
Via MarketMinute
Topics Artificial Intelligence
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats
Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition. 
Via Benzinga
Topics Workforce
This Is What Whales Are Betting On Eli Lilly
 
Via Benzinga
This Drugmaker Stock Slumped 36% In Tuesday’s Premarket Session: Here’s Why
Via Stocktwits
Is the Vanguard Dividend Appreciation ETF a Buy Now?
This stalwart ETF offers a little bit of everything and could outperform the S&P 500 if the Magnificent Seven stocks tumble. 
Via The Motley Fool
Topics ETFs Stocks
One of the Best Stocks to Buy Now?
I ranked Eli Lilly as one of the best stocks to buy starting in 2025. 
Via The Motley Fool
What's Going on With Eli Lilly Stock?
The pharma company is gaining investor attention due to increasingly popular products. 
Via The Motley Fool
Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year
Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark. 
Via Stocktwits
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior. 
Via Benzinga
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns
San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet... 
Via MarketMinute
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'
Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off is excessive. 
Via Benzinga
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks
Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are. 
Via MarketBeat
Why Novo Nordisk Stock Popped Today
For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop. 
Via The Motley Fool
Why Viking Therapeutics Stock Crashed Today
Viking's new GLP-1 weight loss pill is pretty great -- but is it enough to turn the company profitable? 
Via The Motley Fool
Eli Lilly Stock Investors Need to See This
Competition among the makers of weight loss treatments is intensifying. 
Via The Motley Fool
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity patients versus placebo. 
Via Benzinga
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
3 Undervalued Healthcare Stocks You Can Buy Now and Hold Long-Term
The healthcare industry is one of the laggards of 2025. 
Via The Motley Fool
Stock Market Today: S&P 500 Slips, Dow Futures Rise—Intel, Palo Alto, Home Depot In Focus
U.S. stock futures were fluctuating on Tuesday following mostly unchanged moves from Monday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Stocks
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for something BIG." 
Via Benzinga
Topics Bonds
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients. 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
Why Novo Nordisk Stock Popped Monday
Novo Nordisk stock looks so cheap, any good news at all can make it pop. 
Via The Motley Fool
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
1 Stock Down 40% This Year to Buy and Hold
This might be a wonderful entry point for long-term investors. 
Via The Motley Fool
The Best Growth Stock ETF to Invest $100 in Right Now
This ETF has outperformed the S&P 500 handily over various multi-year periods. 
Via The Motley Fool
Topics ETFs Stocks
1 Beaten-Down Stock That Could Soar by the End of the Year
The drugmaker has a major catalyst on the way. 
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.